Serum Oxidative Stress Level Correlates with Clinical Parameters in Chronic Systolic Heart Failure Patients

被引：27

作者：

Amir, Offer ^{[1
]}

Paz, Hagar ^{[2
]}

Rogowski, Ori ^{[2
]}

Barshai, Marina ^{[3
]}

Sagiv, Moran ^{[4
]}

Shnizer, Sergei ^{[5
]}

Reznick, Abraham Z. ^{[3
]}

Amir, Ruthie E. ^{[4
]}

机构：

[1] Lady Davis Carmel Med Ctr, Dept Cardiol, Heart Failure Ctr, Haifa, Israel

[2] Lin Med Ctr, Heart Failure Clin, Haifa, Israel

[3] Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Anat & Cell Biol, IL-31096 Haifa, Israel

[4] Wingate Inst Phys Educ & Sports, Zinman Coll Phys Educ & Sport Sci, Dept Genet & Mol Biol, Netantya, Israel

[5] Lumitest Ltd, Haifa, Israel

来源：

CLINICAL CARDIOLOGY | 2009年 / 32卷 / 04期

关键词：

THERMOCHEMILUMINESCENCE ASSAY; ENDOTHELIAL FUNCTION; NATRIURETIC PEPTIDE; PROGRESSION; DAMAGE; ATENOLOL; INDEXES; DISEASE; PLASMA; FLUID;

D O I：

10.1002/clc.20317

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: Serum oxidative stress (OS) level has an important role in the inflammatory process of heart failure. Hypothesis: The study was designed to analyze serum OS levels in chronic heart failure (HF) patients and to examine the relation between OS levels and other clinical and prognostic parameters of HF. Methods: We studied 82 consecutive chronic symptomatic HF patients with systolic LV dysfunction (ejection fraction < 45%). The serum OS level was determined using thermochemiluminescence assay. We compared the serum OS levels with patients' clinical and prognostic parameters. Results: Higher serum OS levels were associated with higher New York Heart Association class (P = .01), worse renal function (serum urea, creatinine, and creatinine clearance) (P < .001) and higher serum levels of hs-C-reactive protein and N-terminal pro brain natriuretic peptide (P = .001, P < .001, respectively). Conclusions: In chronic systolic HF patients, high serum OS levels correlate with advanced disease and known markers of poor prognosis.

引用

页码：199 / 203

页数：5

共 29 条

[1]

Abrams Jonathan, 2003, Cardiology Clinics, V21, P327, DOI 10.1016/S0733-8651(03)00082-1

[2] ADMA and oxidative stress may relate to the progression of renal disease:: rationale and design of the VIVALDI study [J].

Böger, RH ;

Schwedhelm, E ;

Maas, R ;

Quispe-Bravo, S ;

Skamira, C .

VASCULAR MEDICINE, 2005, 10 :S97-S102

[3] In renal transplanted patients inflammation and oxidative stress are interrelated [J].

Cottone, S. ;

Palermo, A. ;

Vaccaro, F. ;

Raspanti, F. ;

Buscemi, B. ;

Incalcaterra, F. ;

Cerasola, G. .

TRANSPLANTATION PROCEEDINGS, 2006, 38 (04) :1026-1030

[4] Biomarkers of oxidative damage in human disease [J].

Dalle-Donne, I ;

Rossi, R ;

Colombo, R ;

Giustarini, D ;

Milzani, A .

CLINICAL CHEMISTRY, 2006, 52 (04) :601-623

[5] DNA oxidative damage in patients with dialysis treatment [J].

Domenici, FA ;

Vannucchi, MTI ;

Jordao, AA ;

Meirelles, MSS ;

Vannucchi, H .

RENAL FAILURE, 2005, 27 (06) :689-694

[6] Neutrophil superoxide anion-generating capacity, endothelial function and oxidative stress in chronic heart failure: Effects of short- and long-term vitamin C therapy [J].

Ellis, GR ;

Anderson, RA ;

Lang, D ;

Blackman, DJ ;

Morris, RHK ;

Morris-Thurgood, J ;

McDowell, IFW ;

Jackson, SK ;

Lewis, MJ ;

Frenneaux, MP .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (05) :1474-1482

[7] Oxidative stress during myocardial ischaemia and heart failure [J].

Ferrari, R ;

Guardigli, G ;

Mele, D ;

Percoco, GF ;

Ceconi, C ;

Curello, S .

CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (14) :1699-1711

[8] Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension [J].

Flammer, Andreas J. ;

Hermann, Frank ;

Wiesli, Peter ;

Schwegler, Beat ;

Chenevard, Remy ;

Huerlimann, David ;

Sudano, Isabella ;

Gay, Steffen ;

Neidhart, Michel ;

Riesen, Walter ;

Ruschitzka, Frank ;

Luescher, Thomas F. ;

Noll, Georg ;

Lehmann, Roger .

JOURNAL OF HYPERTENSION, 2007, 25 (04) :785-791

[9] A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure [J].

Fragasso, Gabriele ;

Palloshi, Altin ;

Puccetti, Patrizia ;

Silipigni, Carmen ;

Rossodivita, Alessandra ;

Pala, Mariagrazia ;

Calori, Giliola ;

Alfieri, Ottavio ;

Margonato, Alberto .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (05) :992-998

[10] Renal function as a predictor of outcome in a broad spectrum of patients with heart failure [J].

Hillege, HL ;

Nitsch, D ;

Pfeffer, MA ;

Swedberg, K ;

McMurray, JJV ;

Yusuf, S ;

Granger, CB ;

Michelson, EL ;

Östergren, J ;

Cornel, JH ;

de Zeeuw, D ;

Pocock, S ;

van Veldhuisen, DJ .

CIRCULATION, 2006, 113 (05) :671-678

← 1 2 3 →